Sonoma Pharmaceuticals Announces Pricing of Public Offering of Units
November 17 2018 - 11:01AM
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) today announced the
pricing of a “best efforts” public offering of units consisting of
one share of common stock, together with one half of one warrant to
purchase one share of common stock at an exercise price equal to
$1.00 per whole share. The public offering price was $1.00 per
unit. The offering is expected to close on or about November 21,
2018, subject to customary closing conditions.
Certain investors, who would beneficially own,
together with its affiliates and certain related parties, more than
4.99% of the outstanding common stock as a result of the public
offering, can purchase series C convertible preferred stock
convertible into shares of common stock, in lieu of purchasing
common stock.
Dawson James Securities, Inc. is acting as the
lead placement agent and sole book runner.
This offering is being made pursuant to an
effective registration statement on Form S-1 (File No. 333-227806)
previously filed with the Securities and Exchange Commission
(“SEC”) and subsequently declared effective on November 16, 2018. A
prospectus relating to the offering will be filed with the
Securities and Exchange Commission. The securities may be offered
only by means of a written prospectus. When available, copies of
the prospectus will be available on the SEC’s website at
www.sec.gov, or may be obtained by contacting Dawson James
Securities, Inc., Attention: Prospectus Department, 1 North Federal
Highway, 5th Floor, Boca Raton, FL 33432, mmaclaren@dawsonjames.com
or toll free at 866.928.0928.
Sonoma Pharmaceuticals, Inc. intends to use the
net proceeds from the offering for general corporate purposes, new
product launches and working capital.
This press release does not constitute an offer
to sell or a solicitation of an offer to buy, nor shall there be
any sale of these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Sonoma Pharmaceuticals
Sonoma Pharmaceuticals is a specialty pharmaceutical company that
develops and markets solutions for the treatment of
dermatological conditions and advanced tissue care. The company’s
products, which are sold throughout the United States and
internationally, have improved outcomes for more than five million
patients globally by reducing infections, itch, pain, scarring
and harmful inflammatory responses. The company's headquarters are
in Petaluma, California, with manufacturing operations in the
United States and Latin America. European marketing and sales
are headquartered in Roermond, Netherlands. More information can be
found at www.sonomapharma.com.
Forward-Looking
StatementsExcept for historical information herein,
matters set forth in this press release are forward-looking within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995, including statements
about the commercial progress and future financial performance of
Sonoma Pharmaceuticals, Inc. and its subsidiaries (the “Company”).
These forward-looking statements are identified by the use of words
such as “look forward,” “continue,” and “intend,” among others.
Forward-looking statements in this press release are subject to
certain risks and uncertainties inherent in the Company’s business
that could cause actual results to vary, including such risks that
the offering of the shares may not be completed, that the market
price of the Company’s securities is volatile, that the Company has
broad discretion in its use of the proceeds, that stockholders may
face dilution, the Company may not be able to obtain additional
funding, as well as uncertainties relative to varying product
formulations and a multitude of diverse regulatory and marketing
requirements in different countries and municipalities, and other
risks detailed in the Company’s filings with the Securities and
Exchange Commission, including the annual report on Form 10-K,
filed on June 26, 2018. The Company disclaims any obligation to
update these forward-looking statements, except as required by
law.
Sonoma Pharmaceuticals® are trademarks or
registered trademarks of Sonoma Pharmaceuticals, Inc. All other
trademarks and service marks are the property of their respective
owners.
Media and Investor
Contact:Sonoma Pharmaceuticals, Inc.Bob
MillerCFO(925) 787-6218
Sonoma Pharmaceuticals (NASDAQ:SNOA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sonoma Pharmaceuticals (NASDAQ:SNOA)
Historical Stock Chart
From Apr 2023 to Apr 2024